Sign In
Buy IPSC
$2.07
-0.100 (-4.61%)
At Close: Jun 03, 2026
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 19'th Mar 2025
PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cel
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
07:00am, Tuesday, 26'th Nov 2024
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun
What Makes Century Therapeutics (IPSC) a New Buy Stock
01:01pm, Friday, 08'th Nov 2024
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
11:16am, Tuesday, 05'th Nov 2024
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.55 per share a year ago.
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
09:05am, Tuesday, 05'th Nov 2024
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –
Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference
07:00am, Monday, 04'th Nov 2024
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
07:00am, Thursday, 26'th Sep 2024
- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer -
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
09:50am, Thursday, 08'th Aug 2024
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.56 per share a year ago.
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
07:30am, Thursday, 08'th Aug 2024
– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephr
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Tuesday, 09'th Jul 2024
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
11:07am, Thursday, 20'th Jun 2024
Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin ly
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
07:00am, Monday, 03'rd Jun 2024
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
09:40am, Thursday, 09'th May 2024
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.53 per share a year ago.
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
07:30am, Thursday, 09'th May 2024
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE)
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
07:00am, Tuesday, 23'rd Apr 2024
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu
